PMV Pharmaceuticals, Inc.
جودة البيانات: 83%
PMVP
NASDAQ
Manufacturing
Chemicals
KWD 1.41
▼
KWD 0.06
(-4.08%)
6 months return
—
Momentum
Neutral
ROE
-59.43%
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-59.43%
أقل من متوسط القطاع (-54.47%)
ROIC-51.83%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio10.76
Interest Coverage-13.60
التقييم
PE (TTM|NTM)
-0.91 | -1.20
أعلى من متوسط القطاع (-1.49)
P/B Ratio0.58
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -73.61 M
Price History
الاتجاهات المالية
السعر المستهدف للمحللين
4 محللين
Buy
+236.9%
upside to target
الحالي
KWD 1.41
Consensus Target
KWD 4.75
KWD 4.00
أدنى
KWD 6.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-1.20
ربحية السهم المستقبلية
-KWD 1.10
الإيرادات المقدّرة
2.97 M
مفاجآت الأرباح
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -KWD 0.39
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -KWD 0.34 | -KWD 0.41 | -KWD 0.40 | -KWD 0.34 | — | — |
| Estimate | -KWD 0.38 | -KWD 0.39 | -KWD 0.40 | -KWD 0.40 | -KWD 0.39 | -KWD 0.42 |
| المفاجأة | +11.30% | -6.49% | +0.62% | +13.92% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -59.43% · Net Margin: N/A
Profitability
ROE: -59.43% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -77.74 M |
| ROE | -59.43% | ROA | -54.23% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -73.61 M |
| ROIC | -51.83% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 10.76
Safety
D/E: N/A · Current: 10.76| Debt / Equity | N/A | Current Ratio | 10.76 |
| Interest Coverage | -13.60 | Asset Turnover | N/A |
| Working Capital | 120.15 M | Tangible Book Value | 121.00 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -0.91 · EV/EBITDA: N/A
Valuation
P/E: -0.91 · EV/EBITDA: N/A| P/E Ratio | -0.91 | Forward P/E | -1.20 |
| P/B Ratio | 0.58 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 23.77 | Fwd Earnings Yield | N/A |
| FCF Yield | -104.17% | ||
| Market Cap | 70.66 M | Enterprise Value | 34.32 M |
Per Share
EPS: -1.48 · FCF/Share: -1.38
Per Share
EPS: -1.48 · FCF/Share: -1.38| EPS (Diluted TTM) | -1.48 | Revenue / Share | N/A |
| FCF / Share | -1.38 | OCF / Share | -1.38 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 94.68% · CapEx/Rev: N/A
Efficiency
FCF Conv: 94.68% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 94.68% |
| SBC-Adj. FCF | -80.78 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -77.74 M | -58.71 M | -68.96 M | -73.32 M | -57.85 M |
| EPS (Diluted) | -1.48 | -1.14 | -1.44 | -1.61 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -86.21 M | -85.45 M | -80.13 M | -77.04 M | -58.29 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 69.88 M | 58.53 M | 55.89 M | 51.99 M | 36.49 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 6.34 M | 10.66 M | 11.17 M | 3.63 M | 449,000.0 |
| Income Tax | -2.17 M | -16.10 M | 2,000.0 | -9,000.0 | 23,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 116.56 M | 191.29 M | 252.15 M | 270.31 M | 331.57 M |
| Total Liabilities | 11.85 M | 15.21 M | 26.46 M | 24.28 M | 23.01 M |
| Shareholders' Equity | 104.71 M | 176.08 M | 225.69 M | 246.03 M | 308.56 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 37.98 M | 40.88 M | 37.71 M | 108.30 M | 172.47 M |
| Current Assets | 115.23 M | 175.66 M | 207.41 M | 247.01 M | 301.29 M |
| Current Liabilities | 11.42 M | 14.37 M | 14.03 M | 10.83 M | 12.22 M |
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير)
مقارنة بشركات مشابهة في Manufacturing
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير) مقارنة بشركات مشابهة في Manufacturing| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.9 | -1.5 |
| P/B | 0.6 | 1.6 |
| ROE % | -59.4 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"PMVP","listing_kind":"stock","pathname":"/stocks/pmvp","exchange":"NASDAQ","country":"US"}}